Biogen Inc. $BIIB Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its position in shares of Biogen Inc. (NASDAQ:BIIB) by 10.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 38,674 shares of the biotechnology company’s stock after purchasing an additional 3,746 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Biogen were worth $5,417,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Elevation Point Wealth Partners LLC purchased a new stake in Biogen in the second quarter valued at $25,000. Rothschild Investment LLC raised its holdings in Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares during the period. Concord Wealth Partners lifted its position in shares of Biogen by 100.0% during the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 114 shares in the last quarter. True Wealth Design LLC lifted its holdings in Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares in the last quarter. Finally, NewSquare Capital LLC lifted its stake in Biogen by 134.6% in the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Performance

Shares of NASDAQ:BIIB traded down $2.47 on Wednesday, reaching $171.66. The company’s stock had a trading volume of 90,656 shares, compared to its average volume of 1,517,423. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $190.20. The stock’s 50-day moving average is $176.08 and its two-hundred day moving average is $153.99. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04. The stock has a market capitalization of $25.18 billion, a P/E ratio of 15.64, a PEG ratio of 1.44 and a beta of 0.13.

Biogen (NASDAQ:BIIB) last announced its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, beating the consensus estimate of $3.89 by $0.92. The company had revenue of $2.53 billion for the quarter, compared to the consensus estimate of $2.34 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The company’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the business posted $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein lifted their target price on shares of Biogen from $157.00 to $197.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. UBS Group started coverage on Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price objective on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $157.00 target price (up previously from $118.00) on shares of Biogen in a research report on Friday, November 21st. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Finally, Rothschild & Co Redburn lifted their price objective on shares of Biogen from $149.00 to $150.00 and gave the company a “neutral” rating in a report on Monday, October 6th. Ten investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $192.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.